Spruce Biosciences, Inc. files for IPO.

The IPO of Spruce Biosciences will take place on October 8, 2020. Spruce Biosciences is a late stage biopharmaceutical company focused on the development and commercialization of new methods of treating rare endocrine diseases. The company is initially developing its wholly owned candidate tildacerfont as a potential first non-steroidal therapy that will offer significantly improved disease control and reduced steroid burden for patients suffering from classic congenital adrenal hyperplasia.

Listed underwriters of the IPO are Cowen, SVB Leerink, Credit Suisse and RBC Capital Markets.